Cardiff Oncology Inc (NASDAQ:CRDF) shares, rose in value, with the stock price up by 6.38% to the previous day’s close as strong demand from buyers drove the stock to $5.67.
Actively observing the price movement in the last trading, the stock closed the session at $5.33. The value of beta (5-year monthly) was 1.71. Referring to stock’s 52-week performance, its high was $6.42, and the low was $0.94. On the whole, CRDF has fluctuated by 55.34% over the past month.
With the market capitalization of Cardiff Oncology Inc currently standing at about $253.34 million, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2024 – May 06, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.25, which is expected to increase to -$0.24 for fiscal year -$0.97 and then to about -$1.05 by fiscal year 2025. Data indicates that the EPS growth is expected to be -4.30% in 2025, while the next year’s EPS growth is forecast to be -8.20%.
According to the average forecast, sales growth in current quarter could jump down -39.80%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $240k, representing a decrease of -50.80% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CRDF’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 100% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CRDF currently trading nearly 12.61% and 81.78% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 64.48, while the 7-day volatility ratio is showing 10.98% which for the 30-day chart, stands at 15.79%. Furthermore, Cardiff Oncology Inc (CRDF)’s beta value is 1.97, and its average true range (ATR) is 0.62.
A comparison of Cardiff Oncology Inc (CRDF) with its peers suggests the former has fared considerably weaker in the market. CRDF showed an intraday change of 6.38% in last session, and over the past year, it grew by 252.17%%.
Data on historical trading for Cardiff Oncology Inc (NASDAQ:CRDF) indicates that the trading volumes over the past 10 days have averaged 1.28 million and over the past 3 months, they’ve averaged 1.67 million. According to company’s latest data on outstanding shares, there are 44.68 million shares outstanding.
Nearly 8.07% of Cardiff Oncology Inc’s shares belong to company insiders and institutional investors own 12.13% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.81 million shares as on Mar 15, 2024, resulting in a short ratio of 0.71. According to the data, the short interest in Cardiff Oncology Inc (CRDF) stood at 6.30% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 1.19 million. The stock has risen by 283.11% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRDF stock heading into the next quarter.
